SAN DIEGO, June 21, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PT217 for the…
Phanes Therapeutics’ PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA
